Sanofi (NASDAQ: SNY) is one of the Most Undervalued International Stocks According to Analysts. On August 14, Sanofi ...

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not have an impact on its operating profit for 2025. “Sanofi is picking up the ...

The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to ...

Sanofi’s investigational multiple myeloma (MM) therapy has been granted orphan drug designation by the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory disease.

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Sanofi gained its AI platform Pharma.AI in the process. That partnership followed Sanofi’s other AI collaborations, including deals with Exscientia and Owkin. Alex Zhavoronkov, CEO and founder at ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...